The ever-popular annual Clinical Pathology Symposium returned to an in-person format this year in honor of Medical Laboratory Professionals Week and was a hit! The theme for this year’s Symposium was Resilience. Rebound. Readiness. Held in the football-shaped Dining Hall at the NCRC [...]
Dr. Lee Schroeder shares his story.
Please join us in congratulating him on this honor!
Please join us in congratulating Dr. Alexey Nesvizhskii on this outstanding recognition!
Some exciting news is breaking in the Department of Pathology specifically for our laboratory professionals. Medical Laboratory Professionals week is coming soon – the week of April 23, 2023, and with it, a new opportunity is being presented to our phlebotomists, laboratory technicians, and medical laboratory scientists working on the frontlines of our clinical laboratories.
This year, thanks to the generosity of Ms. Suzanne Butch, laboratory professionals through the Senior Technologist level will be eligible to have their certification or recertification fee reimbursed. Laboratory professionals will need to sign-up HERE no later than Monday, May 8th at 8:00 am to be selected at random to have their fees reimbursed. Anyone who’s certification or recertification fees have or will come due in 2023 is eligible to enter. Up to $5,000 in fees will be covered across those whose names will be drawn on May 9th*.
If you wish to help ensure more of our frontline staff have their certification fees covered, and can obtain ongoing professional education, you can contribute to this fund. Certification fees range from $170-$240 and recertification from $95-$110. Larger gifts can help multiple individuals or be used to grow the fund for future use. Even a small contribution can make a big difference to our frontline staff, so make a gift today!
*This story was updated on 4/12/23 to extend the deadline for submission and the drawing date, which were originally April 27 and April 28.
Saturday, March 11th dawned as a typical early Spring day in Michigan, but the day was anything but routine! The North Campus Research Complex (NCRC) at the University of Michigan was teeming with high school students and their parents or guardians, eager to learn more about careers in cancer research. Students learned from career panels as well as through mock tumor boards, DNA extraction activities, and tours of research laboratories [...]
After several decades of hard work by many scientists at the University of Michigan Medical School and elsewhere, an antibody (anti-C5a) has just been approved by the US FDA for treatment of humans who are septic and have developed lung infections with COVID-19, resulting in severe pulmonary dysfunction requiring external lung support. The antibody, anti-C5a, was originally developed in the Dr. Peter Ward laboratory in the early 2000s. The mAb was shown to dramatically reduce lung infections in polymicrobial sepsis in mice.
A recently published research study led by Drs. Sem Phan and Tianju Liu from the Department of Pathology reported new findings that could help scientists predict disease progression and suggest a new immunotherapy target for the treatment of IPF and other fibrotic lung diseases.
These findings uncovered a new role for the immune checkpoint marker (B7-H3) in lung fibrosis that can potentially serve as a novel target for immunotherapy to slow down or abort the progression of lung fibrosis in patients with IPF and other chronic lung fibrotic diseases. In addition, sB7H3 levels in the plasma could serve as a potential marker to predict how quickly the disease progresses in patients and assess responsiveness to therapy, allowing for more informed treatment decisions.